MX2019007176A - Composiciones y metodos para mejorar la eficacia de microbicidas anticonceptivos. - Google Patents

Composiciones y metodos para mejorar la eficacia de microbicidas anticonceptivos.

Info

Publication number
MX2019007176A
MX2019007176A MX2019007176A MX2019007176A MX2019007176A MX 2019007176 A MX2019007176 A MX 2019007176A MX 2019007176 A MX2019007176 A MX 2019007176A MX 2019007176 A MX2019007176 A MX 2019007176A MX 2019007176 A MX2019007176 A MX 2019007176A
Authority
MX
Mexico
Prior art keywords
compositions
efficacy
methods
contraceptive
enhancing
Prior art date
Application number
MX2019007176A
Other languages
English (en)
Inventor
Guthrie Wendell
Original Assignee
Evofem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49758600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019007176(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evofem Inc filed Critical Evofem Inc
Publication of MX2019007176A publication Critical patent/MX2019007176A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

La presente divulgación se refiere a composiciones y métodos para la anticoncepción, que también mejoran la eficacia de los microbicidas; tales composiciones sirven para el propósito dual de prevenir el embarazo y disminuir el riesgo de propagar enfermedades de transmisión sexual; más específicamente, las composiciones y los métodos se refieren a composiciones microbicidas anticonceptivas y antivirales sinérgicas que comprenden una combinación de un microbicida anticonceptivo y un agente antiviral en un vehículo ácido que mejora la eficacia tanto del microbicida anticonceptivo como del agente antiviral.
MX2019007176A 2012-06-13 2014-12-11 Composiciones y metodos para mejorar la eficacia de microbicidas anticonceptivos. MX2019007176A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261659368P 2012-06-13 2012-06-13

Publications (1)

Publication Number Publication Date
MX2019007176A true MX2019007176A (es) 2019-08-16

Family

ID=49758600

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014015307A MX365905B (es) 2012-06-13 2013-03-15 Composiciones y métodos para mejorar la eficacia de microbicidas anticonceptivos.
MX2019007176A MX2019007176A (es) 2012-06-13 2014-12-11 Composiciones y metodos para mejorar la eficacia de microbicidas anticonceptivos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014015307A MX365905B (es) 2012-06-13 2013-03-15 Composiciones y métodos para mejorar la eficacia de microbicidas anticonceptivos.

Country Status (17)

Country Link
US (6) US20150202216A1 (es)
EP (2) EP3308771A1 (es)
JP (2) JP6352907B2 (es)
KR (1) KR102062599B1 (es)
CN (2) CN110693812A (es)
AP (1) AP2014008149A0 (es)
AU (2) AU2013274815B2 (es)
BR (1) BR112014030984B1 (es)
EA (1) EA201590008A1 (es)
HK (1) HK1208809A1 (es)
IL (1) IL235812B (es)
MX (2) MX365905B (es)
NZ (1) NZ703203A (es)
SG (1) SG11201408243VA (es)
UA (1) UA115876C2 (es)
WO (1) WO2013187984A1 (es)
ZA (1) ZA201500111B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110693812A (zh) * 2012-06-13 2020-01-17 伊沃菲姆股份有限公司 用于增强避孕杀微生物剂有效性的组合物和方法
US11337989B2 (en) 2013-12-19 2022-05-24 Evofem, Inc. Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
CN110225750A (zh) * 2016-10-04 2019-09-10 伊沃菲姆股份有限公司 细菌性阴道病的治疗和预防方法
USD920853S1 (en) * 2018-09-14 2021-06-01 Porsche Lizenz—und Handelsgesellschaft mbH & Co. KG Bicycle
US11850303B2 (en) 2020-10-27 2023-12-26 Uqora, Inc. Gel and a suppository and methods to provide the gel and suppository

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1213323B (it) * 1986-08-07 1989-12-20 Crinos Industria Farmaco Composizione per uso locale ad atti vita' spermicida virulicida ,disinfettante e/o battericida
US4999342A (en) * 1988-08-16 1991-03-12 Ortho Pharmaceutical Corporation Long lasting contraceptive suppository composition and methods of use
JP3202365B2 (ja) 1992-12-04 2001-08-27 株式会社紀文フードケミファ オリゴマンヌロン酸を重合度によって分離する方法
US5592949A (en) 1994-06-29 1997-01-14 Moench; Thomas R. Device for acidic buffering and method for inactivation of pathogens
US5667492A (en) 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
FR2728464B1 (fr) * 1994-12-22 1997-04-30 Innothera Lab Sa Forme galenique unitaire, son procede d'obtention et ses utilisations
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
WO2001038284A1 (en) 1999-11-24 2001-05-31 Cargill Dow Llc Improved lactic acid processing; methods; arrangements; and, products
US6706276B2 (en) * 2000-03-07 2004-03-16 Rush-Presbyterian-St. Luke's Medical Center Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
JP2009102407A (ja) 2001-03-08 2009-05-14 Rohto Pharmaceut Co Ltd Ｇリッチなアルギン酸含有組成物
US20020177624A1 (en) 2001-03-16 2002-11-28 Calvin Hanna Acetate-lactate buffering vaginal gel and for method of making same and treating bacterial vaginosis
ITMI20010913A1 (it) 2001-05-04 2002-11-04 Univ Pavia Composizioni a rilascio controllato di acido lattico a livello vaginale
US20040242459A1 (en) 2001-06-11 2004-12-02 Forrest Michael J Method for treating inflammatory diseases by administering a ppar-delta agonist
US20060105008A1 (en) 2002-03-28 2006-05-18 Nawaz Ahmad Compositions and methods for reducing vaginal pH
US20130150810A1 (en) 2002-04-30 2013-06-13 The Population Council, Inc. Intravaginal ring for the delivery of unique combinations of antimicrobial compositions
WO2004011032A1 (ja) 2002-07-26 2004-02-05 Mikasa Seiyaku Co., Ltd. 外用剤
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
ES2752773T3 (es) 2003-06-13 2020-04-06 Idh Holding Aps Tratamiento de los síntomas asociados a la vaginosis bacteriana
US20050272700A1 (en) 2004-05-10 2005-12-08 Servet Buyuktimkin Topical treatment and prevention of human papilloma virus (HPV) infection
RU2257197C1 (ru) 2004-05-12 2005-07-27 Дулькис Мария Дмитриевна Вагинальные суппозитории, обладающие контрацептивным действием
UA93354C2 (ru) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
WO2008056786A1 (fr) 2006-11-10 2008-05-15 Rohto Pharmaceutical Co., Ltd. Composition pour application cutanée ou par voie muqueuse
US7659259B2 (en) 2006-12-21 2010-02-09 Bausch & Lomb Incorporated Method of treating inflammation of the eye
DK2142186T3 (da) 2007-03-30 2014-08-04 Laccure Ab Anvendelse af oligomerer af mælkesyre ved behandling af gynækologiske infektioner
AU2008256689A1 (en) * 2007-05-24 2008-12-04 New York Blood Center Inc. Rapidly dispersible vaginal tablet that provides a bioadhesive gel
US8464245B2 (en) 2007-06-27 2013-06-11 Flexera Software Llc Method and system for software virtualization directly from an installation package
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
WO2009127825A1 (en) * 2008-04-16 2009-10-22 Cipla Limited Topical combinations comprising an antimycotic agent and an antiviral agent
CN101559036B (zh) * 2008-04-18 2012-02-08 上海医药工业研究院 一种阴道用避孕凝胶组合物及其制备方法和应用
WO2009155118A1 (en) * 2008-05-30 2009-12-23 Reprotect, Inc. Compositions and methods for inactivation of pathogens at genital tract surfaces
EP2130531A1 (en) 2008-06-04 2009-12-09 Rolf Kullgren AB Vaginal suppository comprising lactic acid
BRPI0803568B8 (pt) * 2008-08-14 2021-05-25 Biolab San Us Farm Ltda composição mucoaderente
US20120070476A1 (en) 2009-05-29 2012-03-22 Moench Thomas R Compositions and Methods for Inactivation of Pathogens at Genital Tract Surfaces
WO2010142761A1 (en) 2009-06-10 2010-12-16 Ultimorphix Technologies B.V. The succinate of tenofovir disoproxil
TW201247240A (en) 2011-05-02 2012-12-01 Aptalis Pharmatech Inc Rapid dissolve tablet compositions for vaginal administration
CA3054236A1 (en) 2011-06-28 2013-01-03 Chemo Research Sl High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis
US20150164837A1 (en) 2012-03-19 2015-06-18 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Use of amphoteric surfactants for the prevention and treatment of pathogenic vaginal biofilms in vaginal infections
CN110693812A (zh) * 2012-06-13 2020-01-17 伊沃菲姆股份有限公司 用于增强避孕杀微生物剂有效性的组合物和方法
US20150246065A1 (en) 2012-09-14 2015-09-03 Cipla Limited Topical Pharmaceutical Composition
WO2015027071A1 (en) 2013-08-21 2015-02-26 Georgia Regents Research Institute, Inc. Gpr81 agonists and methods thereof for promoting production of secretory iga
WO2015070072A1 (en) 2013-11-07 2015-05-14 Evofem, Inc. Methods for manufacturing contraceptive microbicides with antiviral properties
US11337989B2 (en) 2013-12-19 2022-05-24 Evofem, Inc. Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound
AU2015201042A1 (en) 2014-02-28 2015-09-17 Macfarlane Burnet Institute For Medical Research And Public Health Pty Ltd Therapeutic Method
US20190209502A1 (en) 2016-09-12 2019-07-11 Evofem, Inc. Combination gel for sexually transmitted infections
CN110225750A (zh) 2016-10-04 2019-09-10 伊沃菲姆股份有限公司 细菌性阴道病的治疗和预防方法

Also Published As

Publication number Publication date
JP2015519395A (ja) 2015-07-09
CN110693812A (zh) 2020-01-17
EP2861215A1 (en) 2015-04-22
JP6738573B2 (ja) 2020-08-12
AU2013274815B2 (en) 2017-04-20
MX2014015307A (es) 2015-07-06
CN104487054A (zh) 2015-04-01
US20160008276A1 (en) 2016-01-14
NZ703203A (en) 2016-07-29
AU2017206199B2 (en) 2019-03-28
HK1208809A1 (en) 2016-03-18
KR102062599B1 (ko) 2020-01-06
KR20150018636A (ko) 2015-02-23
JP6352907B2 (ja) 2018-07-04
IL235812B (en) 2020-05-31
AP2014008149A0 (en) 2014-12-31
US20190133978A1 (en) 2019-05-09
ZA201500111B (en) 2016-01-27
MX365905B (es) 2019-06-18
US9566232B2 (en) 2017-02-14
US11439610B2 (en) 2022-09-13
UA115876C2 (uk) 2018-01-10
AU2017206199A1 (en) 2017-08-03
EP3308771A1 (en) 2018-04-18
US20200147015A1 (en) 2020-05-14
SG11201408243VA (en) 2015-01-29
US20150202216A1 (en) 2015-07-23
IL235812A0 (en) 2015-01-29
BR112014030984B1 (pt) 2022-05-24
WO2013187984A1 (en) 2013-12-19
US11992472B2 (en) 2024-05-28
US10568855B2 (en) 2020-02-25
JP2018109034A (ja) 2018-07-12
EP2861215A4 (en) 2015-04-22
US20230241013A1 (en) 2023-08-03
EA201590008A1 (ru) 2015-05-29
BR112014030984A2 (pt) 2017-06-27
AU2013274815A1 (en) 2015-01-22
US20170128396A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
MX2019007176A (es) Composiciones y metodos para mejorar la eficacia de microbicidas anticonceptivos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12016500871A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2015003262A (es) Composicion farmaceutica topica.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
MY185108A (en) Method for treatment of labor arrest
MX2016005092A (es) Composiciones farmaceuticas de estradiol insertadas en la vagina y metodos.
PL2991642T3 (pl) Kompozycje przeciwdrobnoustrojowe do zastosowania w leczeniu zapalenia sutka u przeżuwaczy
MX2013013182A (es) Tratamiento de la mastitis.
MX2015001007A (es) Composicion de misoprostol.
TN2015000197A1 (en) Use and application regimen of a pharmaceutical composition containing levonorgestrel and a cox inhibitor for on-demand contraception
MX2014007523A (es) Anillo vaginal que comprende meloxicam y un agente modulador de la liberacion del principio activo, util como anticonceptivo de uso continuo en mujeres.
HK1205000A1 (en) Intrauterine application of 18-methyl-15ss,16ss-methylene-19-nor-20- spirox-4-en-3-one systems, intrauterine systems containing 18-methyl- 15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one, as well as the use thereof in contraception and gynaecological therapy 18--1516--19--20--4--3- 18--1516--19--20--4--3-
IN2013MU03582A (es)
MX2022002614A (es) El uso de un pesario que comprende una capsula que contiene estradiol y un agente solubilizante para el tratamiento de la atrofia vulvovaginal.
HK1206271A1 (en) Application of 18-methyl-15,16-methylene-19-nor-20-spirox-4-en-3- one in the treatment of menorrhagia, as well as intrauterine systems containing 18-methyl-15,16-methylene-19-nor-20-spirox-4-en-3-one for treating uterine bleeding disorders 18--1516--19--20--4--3- 18--1516--19-- 20--4--3-
IN2013MU02732A (es)
IN2012DE00873A (es)